THE PUBLIC campaign against patent policies in the US is important for the rest of the world, because it is the Washington model that has set global standards for the stifling monopoly rights enjoyed by innovator drug companies. So when a group of leading public organisations recently asked the US Secretary of Health and Human Services Xavier Becerra to use his executive power to override patent rights on six important therapies, it signals the growing pressure on the US administration to curtail monopoly patent rights on the drugs it helps to develop; either through research collaboration with the National Institutes of Health (NIH) or public funding. Such a measure would widen access to life-saving medicines and reduce their prices.
The COVID-19 pandemic has prompted health activists to pursue such a strategy, spurred by the dispute between NIH and Moderna Inc over patent rights to the biotech company's mRNA COVID-19 vaccine. Moderna's vaccine was developed in collaboration with scientists of NIH who had earlier done the vital groundwork on mRNA technology, the reason why the vaccine could be developed in a short time. Yet, Moderna excluded key NIH scientists when it filed patent claims on the vaccine (see 'Bizarre patent tussles over a COVID-19 jab', Down To Earth 1-15 March, 2022) allowing it to rake in huge profits. Who really owns the intellectual property rights (IPRS) on the vaccine is a vital question in these pandemic times. If NIH insists on its innovator rights, that means the public organisation can license the technology to companies of its choice, in addition to receiving a share of the US $18 billion profits that Moderna is forecast to earn this year.
Diese Geschichte stammt aus der May 01, 2022-Ausgabe von Down To Earth.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der May 01, 2022-Ausgabe von Down To Earth.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
Trade On Emissions
EU's Carbon Border Adjustment Mechanism, a tariff on imports, is designed to protect European industries in the guise of climate action.
'The project will facilitate physical and cultural decimation of indigenous people'
The Great Nicobar Project has all the hallmarks of a disaster-seismic, ecological, human. Why did it get the go-ahead?
TASTE IT RED
Popularity of Karnataka's red jackfruit shows how biodiversity can be conserved by ensuring that communities benefit from it
MANY MYTHS OF CHIPKO
Misconceptions about the Chipko movement have overshadowed its true objectives.
The politics and economics of mpox
Africa's mpox epidemic stems from delayed responses, neglect of its health risks and the stark vaccine apartheid
Emerging risks
Even as the world gets set to eliminate substances threatening the ozone layer, climate change and space advancement pose new challenges.
JOINING THE CARBON CLUB
India's carbon market will soon be a reality, but will it fulfil its aim of reducing emissions? A report by PARTH KUMAR and MANAS AGRAWAL
Turn a new leaf
Scientists join hands to predict climate future of India's tropical forests
Festering troubles
The Democratic Republic of Congo struggles to contain mpox amid vaccine delays, conflict and fragile healthcare.
India sees unusual monsoon patterns
THE 2024 southwest monsoon has, between June 1 and September 1, led to excess rainfall in western and southern states such as Gujarat, Maharashtra and Tamil Nadu, while others like Nagaland, Manipur and Punjab recorded a deficit.